Breaking News Instant updates and real-time market news.

KNSA

Kiniksa

$13.98 /

-0.02 (-0.14%)

09:52
01/13/20
01/13
09:52
01/13/20
09:52

Kiniksa reiterates 2020 clinical data readouts

Kiniksa Pharmaceuticals announced recent pipeline progress and upcoming 2020 clinical milestones. Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa will provide further detail in a corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. Recent Pipeline Progress and Expected 2020 Clinical Data Readouts: Rilonacept: Kiniksa has achieved its enrollment target for RHAPSODY, a global, randomized-withdrawal design, pivotal Phase 3 trial of rilonacept in patients with recurrent pericarditis. The company expects top-line data in the second half of 2020. Kiniksa recently announced the U.S. Food and Drug Administration granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis. Kiniksa's Breakthrough Therapy application was based on final data from an open-label Phase 2 clinical trial of rilonacept in a range of recurrent pericarditis populations. Mavrilimumab: Kiniksa has achieved its enrollment target for a global Phase 2 proof-of-concept trial of mavrilimumab in patients with giant cell arteritis. The company expects top-line data in the second half of 2020. Kiniksa and Kite, a Gilead company, recently announced a clinical collaboration evaluating the investigational combination of Yescarta and mavrilimumab in relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Preclinical evidence shows the potential for interruption of granulocyte macrophage colony stimulating factor signaling to disrupt chimeric antigen receptor T cell-mediated inflammation without disrupting anti-tumor efficacy. KPL-716: Kiniksa expects top-line data from a Phase 2a clinical trial of KPL-716 in patients with prurigo nodularis in the first half of 2020. Kiniksa expects interim data from cohorts of a Phase 2 clinical trial of KPL-716 in diseases characterized by chronic pruritus in the first half of 2020. KPL-404: Kiniksa is enrolling and dosing subjects in a single-ascending-dose Phase 1 clinical trial of KPL-404 in healthy volunteers. The first-in-human trial will provide safety data and pharmacokinetics as well as receptor occupancy and T-cell Dependent Antibody Response. Top-line data are expected in the second half of 2020. KPL-045: Based on preclinical data in the context of Kiniksa's portfolio, the company no longer plans to progress KPL-045 into clinical development.

KNSA Kiniksa
$13.98 /

-0.02 (-0.14%)

12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
03/11/19 Barclays
Kiniksa initiated with an Overweight at Barclays

TODAY'S FREE FLY STORIES

Hot Stocks
Accenture acquires VanBerlo, terms not disclosed » 05:53
02/19/20
02/19
05:53
02/19/20
05:53
ACN

Accenture

$213.78 /

+1.4 (+0.66%)

Accenture has acquired…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
ICL announces acquisition of Growers Holdings » 05:42
02/19/20
02/19
05:42
02/19/20
05:42
ICL

ICL

$3.87 /

-0.245 (-5.96%)

ICL announced that it has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Orica upgraded to Buy from Hold at Jefferies » 05:41
02/19/20
02/19
05:41
02/19/20
05:41
OCLDY

Orica

$0.00 /

+ (+0.00%)

Jefferies analyst Richard…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Initiation
Camtek initiated with a Buy at Needham » 05:35
02/19/20
02/19
05:35
02/19/20
05:35
CAMT

Camtek

$12.00 /

+ (+0.00%)

Needham analyst Quinn…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
Hot Stocks
Nano Dimension establishes headquarters for Americas in south Florida » 05:34
02/19/20
02/19
05:34
02/19/20
05:34
NNDM

Nano Dimension

$1.34 /

+0.06 (+4.69%)

Nano Dimension announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
SI-Bone initiated with a Buy at Needham » 05:28
02/19/20
02/19
05:28
02/19/20
05:28
SIBN

SI-Bone

$20.60 /

+0.07 (+0.34%)

Needham analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Chiyoda downgraded to Hold from Buy at Jefferies » 05:25
02/19/20
02/19
05:25
02/19/20
05:25
CHYCY

Chiyoda

$0.00 /

+ (+0.00%)

Jefferies analyst Thanh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Varta upgraded to Hold from Reduce at Commerzbank » 05:23
02/19/20
02/19
05:23
02/19/20
05:23
VARGF

Varta

$0.00 /

+ (+0.00%)

Commerzbank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
Golden Ocean upgraded to Hold from Sell at Pareto » 05:22
02/19/20
02/19
05:22
02/19/20
05:22
GOGL

Golden Ocean

$4.51 /

-0.08 (-1.74%)

Pareto analyst Eirik…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Cognizant initiated with an Underweight at Atlantic Equities » 05:19
02/19/20
02/19
05:19
02/19/20
05:19
CTSH

Cognizant

$68.83 /

+0.38 (+0.56%)

Atlantic Equities…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Accenture initiated with an Overweight at Atlantic Equities » 05:19
02/19/20
02/19
05:19
02/19/20
05:19
ACN

Accenture

$213.78 /

+1.4 (+0.66%)

Atlantic Equities…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Fortescue Metals downgraded to Underperform from Sector Perform at RBC Capital » 05:19
02/19/20
02/19
05:19
02/19/20
05:19
FSUGY

Fortescue Metals

$0.00 /

+ (+0.00%)

RBC Capital analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Fluor downgraded to Hold from Buy at Canaccord » 05:17
02/19/20
02/19
05:17
02/19/20
05:17
FLR

Fluor

$14.80 /

-4.74 (-24.26%)

Canaccord Genuity analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Epiroc downgraded to Reduce from Hold at Kepler Cheuvreux » 05:16
02/19/20
02/19
05:16
02/19/20
05:16
EPOKY

Epiroc

$0.00 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Agilent price target raised to $96 from $86 at Piper Sandler » 05:15
02/19/20
02/19
05:15
02/19/20
05:15
A

Agilent

$84.75 /

-1.1 (-1.28%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Eaton forms joint venture with Abunayyan Holding » 05:14
02/19/20
02/19
05:14
02/19/20
05:14
ETN

Eaton

$104.44 /

+0.88 (+0.85%)

Eaton and Abunayyan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
AtriCure price target raised to $50 from $40 at Piper Sandler » 05:12
02/19/20
02/19
05:12
02/19/20
05:12
ATRC

AtriCure

$43.15 /

-0.73 (-1.66%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Genentech says Tecentriq granted priority review by FDA » 05:12
02/19/20
02/19
05:12
02/19/20
05:12
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Outfront Media price target raised to $35 from $32 at Imperial Capital » 05:10
02/19/20
02/19
05:10
02/19/20
05:10
OUT

Outfront Media

$30.87 /

+0.02 (+0.06%)

Imperial Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Bluebird pushed Biologics License Application to second half, says Piper Sandler » 05:09
02/19/20
02/19
05:09
02/19/20
05:09
BLUE

Bluebird Bio

$88.16 /

-0.98 (-1.10%)

The Zynteglo European…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Dentsply Sirona added to Select List, target raised to $66 at Stifel » 05:04
02/19/20
02/19
05:04
02/19/20
05:04
XRAY

Dentsply Sirona

$57.91 /

+0.12 (+0.21%)

Stifel analyst Jonathan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Culp, Inc. downgraded to Hold from Buy at Stifel » 05:00
02/19/20
02/19
05:00
02/19/20
05:00
CULP

Culp, Inc.

$11.07 /

-0.68 (-5.79%)

Stifel analyst John Baugh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Diamondback Energy doubles dividend to $1.50 per year » 04:57
02/19/20
02/19
04:57
02/19/20
04:57
FANG

Diamondback Energy

$74.55 /

-0.39 (-0.52%)

Diamondback Energy said…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Independent Bank management to meet with Piper Sandler » 04:55
02/19/20
02/19
04:55
02/19/20
04:55
IBCP

Independent Bank

$21.63 /

-0.38 (-1.73%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Week of 2/15 Redbook to be released at 08:55  04:55
02/19/20
02/19
04:55
02/19/20
04:55
 

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.